2m 2m 2m 2m 2m 2m 2m
SAB BIOTHERAP (SABS)
NASDAQ
$3.38-$0.10 (-3.02%)
Price as of Jun 03, 2026 5:54 PM EDT- $275.3MMarket Cap
- 87.10%1-Year Change
- BiotechnologyIndustry
SAB BIOTHERAP (SABS)
$3.38-$0.10 (-3.02%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 1.3M -40.94% | 2.2M -90.63% | 23.9M -60.73% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 1.3M -40.94% | 2.2M -90.63% | 23.9M -33.37% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -34.4M +13.56% | -30.3M +83.18% | -16.5M -54.68% | -36.4M -36.28% | |
Depreciation and Amortization Expense | 3.0M -36.36% | 4.7M +28.81% | 3.7M +15.26% | 3.2M +112.91% | |
Total Operating Expenses | 49.0M +10.67% | 44.2M +9.72% | 40.3M -23.68% | 52.8M -28.88% | |
Operating Profit | -49.0M +14.08% | -42.9M +12.70% | -38.1M +31.67% | -28.9M +115.91% | |
Interest Income | 1.4M +11.36% | 1.3M +119.84% | 584,966 +723.06% | 71,072 +207.47% | |
Interest Expense | N/A N/A | N/A N/A | -315,284 +4.54% | -301,584 +2.42% | |
Interest Income and Expense and Net | 1.4M +11.36% | 1.3M +376.86% | 269,682 +216.99% | -230,512 -15.05% | |
Total Nonoperating Income and Expense | 62.2M +606.71% | 8.8M +313.80% | -4.1M -140.37% | 10.2M +185,804.56% | |
Income before Taxes | -49.0M +14.08% | -42.9M +1.70% | -42.2M +125.45% | -18.7M +39.74% | |
Income Taxes | 0 N/A | 0 N/A | 0 -100.00% | 25,629 N/A | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | 13.3M +138.92% | -34.1M -19.17% | -42.2M +125.14% | -18.7M +9.31% | |
Net Income from Continuing Operations Applicable to Common | 13.3M +138.92% | -34.1M -19.17% | -42.2M +125.45% | -18.7M +9.16% | |
Basic EPS and Net Income | 0.22 +105.98% | -3.68 -51.83% | -7.64 +1,676.74% | -0.43 -31.75% | |
Diluted EPS and Net Income | -0.79 -78.53% | -3.68 -51.83% | -7.64 +1,676.74% | -0.43 -31.75% | |
Basic Weighted Average Shares | 19.3M +108.51% | 9.3M +67.74% | 5.5M -87.31% | 43.5M +59.20% | |
Diluted Weighted Average Shares | 61.3M +562.28% | 9.3M +67.74% | 5.5M -87.31% | 43.5M +59.20% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 10.5M +18.03% | 8.9M -84.27% | 56.6M +275.93% | 15.0M -54.69% | |
Short-Term Investments | 86.1M +625.72% | 11.9M N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 96.6M +365.27% | 20.8M -63.30% | 56.6M +275.93% | 15.0M -54.69% | |
Total Current Assets | 101.1M +324.73% | 23.8M -59.61% | 58.9M +166.58% | 22.1M -55.97% | |
Accumulated Depreciation | 17.5M +20.19% | 14.6M +47.04% | 9.9M +57.87% | 6.3M +94.98% | |
Property and Plant and Equipment and Net | 13.3M -13.42% | 15.4M -22.13% | 19.7M -15.11% | 23.3M -4.37% | |
Total Long-Term Assets | 13.3M -13.42% | 15.4M -22.13% | 19.7M -15.11% | 23.3M -4.37% | |
Total Assets | 172.8M +291.01% | 44.2M -47.35% | 83.9M +64.90% | 50.9M -37.26% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 275,849 -73.75% | 1.1M +36.00% | 772,665 -57.00% | |
Total Current Liabilities | 10.7M +33.86% | 8.0M -26.21% | 10.8M -27.88% | 15.0M -43.33% | |
Total Long-Term Debt | N/A N/A | 275,849 N/A | 0 -100.00% | 541,644 N/A | |
Total Long-Term Liabilities | 7.5M +7.78% | 7.0M -43.83% | 12.4M +1,719.24% | 682,155 -94.49% | |
Total Liabilities | 21.3M +16.95% | 18.2M -31.59% | 26.6M +34.24% | 19.8M -53.40% | |
Retained Earnings | -110.9M -10.69% | -124.2M +37.87% | -90.1M +88.14% | -47.9M +64.34% | |
Total Stockholders Equity | 151.5M +483.35% | 26.0M -54.68% | 57.3M +84.49% | 31.1M -19.43% | |
Total Shares Outstanding | 47.6M +412.55% | 9.3M +0.69% | 9.2M -81.69% | 50.4M +15.88% | |
Cash Flow | |||||
Cash from Operating Activities | -44.8M +30.57% | -34.3M +36.52% | -25.1M +7.08% | -23.5M -1,280.73% | |
Capital Expenditures | 933,156 +176.69% | 337,262 +71.07% | 197,154 -90.90% | 2.2M -80.20% | |
Cash from Investing Activities | -121.7M +917.42% | -12.0M +7,733.63% | -152,704 -92.69% | -2.1M -80.90% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 168.3M +14,452.36% | -1.2M -101.76% | 66.8M +6,250.81% | 1.1M -97.07% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -3,244.87% +90.81% | -1,700.56% +1,305.73% | -120.97% +449.86% | |
Return on Assets | 12.23% +122.98% | -53.23% -14.94% | -62.58% +120.47% | -28.39% -32.56% | |
Return on Equity | 14.96% +118.26% | -81.92% -14.23% | -95.51% +77.37% | -53.85% -39.44% | |
Revenue Growth | -100.00% +144.28% | -40.94% -54.83% | -90.63% +49.23% | -60.73% N/A | |
Current Ratio | 9.46 +217.31% | 2.98 -45.27% | 5.45 +269.63% | 1.47 -22.32% | |
Cash Ratio | 0.98 -11.82% | 1.12 -78.68% | 5.23 +421.23% | 1.00 -20.04% | |
Debt-to-Equity Ratio | N/A N/A | 0.02 +15.85% | 0.02 -56.74% | 0.04 -9.23% | |
Debt-to-Assets Ratio | N/A N/A | 0.01 0.00% | 0.01 -51.55% | 0.03 +16.74% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow